Analysis Of Clinical Characteristic And Prognostic Factors In Primary Ovarian Malignant Tumor

Objective: To summarize the clinical features and prognosis of malignant ovarian tumors, and to study theprognostic factors of malignant ovarian tumors, through analyzing the clinical data and following up thepatients with primary malignant ovarian tumor, to provide the basis for standardized diagnosis andtreatment, so as to provide the basis for improving the prognosis of patients and improving their survivalrates.Methods:103cases of primary malignant ovarian tumor first diagnosed by histopathology and treated ingynecologic and obstetrics department of The First Affiliated Hospital of Medical college,ShiheziUniversity during the period from Jan.2003to Jul.2012were retrospectively analyzed and followed.Thepatient’s general condition, the symptoms and signs, auxiliary examination results, factors associated withtreatment, pathological features were included as the study factors. Adopt outpatient follow-up, telephoneor letter followed up ways to obtain the survival rate of patients. All the data were analyzed by SPSS17.0statistical software. The Kaplan-Meier method was used for single variable data analysis, the Log-rankmethod was used to examine differences of survival rate (P <0.05was statistically significant).The Coxproportional hazards model was applied to assess the independent prognostic factors.(P <0.05wasstatistically significant).Results:(1)103cases of patients with onset age of16-75years old, average age was (50.19±13.89)yearsold; for FIGO staging,53cases (51.5%) were in early stage(I-II), while50cases (48.5%) were inadvanced stage(III-IV); The histological types of the tumors were as follows:47cases (45.6%)withserous epithelial malignant tumor,37cases (35.9%with non serous epithelial malignant tumor,19cases(18.5%) with non epithelial malignant tumor; for pathological differentiation,45cases (43.7%)withwell-differentiated (G1),58cases (56.3%)with poorly differentiated (G2-G3).(2) By the end of December31,2012, of103patients there were77cases (74.8%) survived,26cases(25.2%) died of late complications of tumor. The longest follow-up time was110months, the shortest was5months, the average follow-up time was (35.61±23.21) months. All patients of1years,3years,5yearssurvival rates were83%,74%,63%.(3) Kaplan-Meier single factor analysis showed: There were no significant relationship between familyhistory of malignant tumor, basis disease history or not, chemotherapy regimen,chemotherapy cycle, tumorsize, tumour nature and the prognosis of malignant ovarian tumors;age of onset, preoperative serumCA125, operation mode, operation pathological staging, the volume of ascites, pathological differentiation,pathological type of tumor, postoperative residual tumor size, tumour laterality, cytological examination ofascites sediment without special cell or not, lymph node dissection of11parameters may be effects ofovarian malignant tumor related prognostic factors (P <0.05).(4)COX multivariate regression analysis showed:Operation pathological staging, pathologicaldifferentiation were the independent prognostic factors of malignant ovarian tumor. The risk of death forpatients with advanced stages(III-IV)was26.336times of the early stage(I-II)ones and95%confidence interval was [2.083-332.908];The risk of death for patients with poorly differentiated (G2-G3)was5.034times of the well-differentiated (G1)ones and95%confidence interval was [1.032-24.550].Conclusion: Age of onset, preoperative serum CA125, operation mode, operation pathological staging, thevolume of ascites, pathological differentiation,, pathological type of tumor, postoperative residual tumorsize, tumour laterality, cytological examination of ascites sediment without special cell or not, lymph nodedissection of11parameters may be effects of ovarian malignant tumor related prognostic factors. Whileoperation pathological staging, pathological differentiation, were the independent prognostic factors ofprimary malignant ovarian tumor. Early detection, early diagnosis, and reasonable treatment is the key toimprove the prognosis of patients with primary ovarian malignant tumor.